Capricor Therapeutics Inc — Balance Sheet (NASDAQ:CAPR) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Total assets 34.62 M41.33 M50.09 M58.73 M170.48 M Total liabilities 6.42 M9.96 M38.31 M36.13 M25.02 M Total equity 28.2 M31.37 M11.79 M22.6 M145.46 M Total liabilities & shareholders' equities 34.62 M41.33 M50.09 M58.73 M170.48 M Total debt ————— Net debt —————

新闻

Oppenheimer重申Capricor股票"优于大盘"评级，维持54美元目标价

Oppenheimer reiterates Outperform rating on Capricor stock, maintains $54 target

CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February

Capricor to submit HOPE-3 data to FDA for DMD therapy review

Cantor Fitzgerald重申Capricor Therapeutics股票评级

Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald

Cantor Fitzgerald重申Capricor股票"增持"评级

Cantor Fitzgerald reiterates Overweight rating on Capricor stock

Capricor Therapeutics Stock: A High Risk/High Reward Name (NASDAQ:CAPR)

Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

Piper Sandler维持Capricor股票评级，将其列为2026年首选